BUSINESS● LOWSep 10 · Sep 10, 2026, 3:49 PM

Revolution a new overweight at Morgan Stanley on RAS-targeted oncology franchise

Seeking Alpha Tech · global

Morgan Stanley has given a new 'overweight' rating to Revolution based on its RAS-targeted oncology franchise. This indicates a positive outlook from the financial firm on the company's performance in cancer treatment development.

Read at Seeking Alpha Tech Ask the Analyst about this

GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.

See it on the live mapEvents around the world right now

More in Business

BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSEC BUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSEC BUSINESS29m agoKarnataka turns to U.K. roadshows to revive declining NRI tourist footfallThe Hindu BUSINESS38m agoBangladesh garment protests shut factories, threatening global supply chainsSeeking Alpha Tech